Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 48.58$. Average daily volumn in 3 months 2.02M. Market cap 135.91B

Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 54.42$. Total volume : 2.03M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price

Previous Close53.97
Day Range54.16-54.52
Bid53.19 x 800
Ask54.31 x 900
Average Volume2.02M
Market Cap135.91B
52 Week Range36.91-58.10
Trailing P/E15.07
Foward P/E10.95
Dividend (Yield %)3.50%
Ex-Dividend Date2023-05-25

Financial Details

According to Sanofi's financial reports the company's revenue in 2022 were 45.39B an increase( +15.38%) over the years 2021 revenue that were of 39.17B. In 2022 the company's total earnings were 8.37B while total earnings in 2021 were 6.22B( +33.33%).

Loading ...


Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers po... liomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
Total Assets:
Total Cash:

News about "Sanofi"

Sanofi to Spin Off India Consumer Unit

Source from : TipRanks on MSN - 2 days ago

Global healthcare major Sanofi (NASDAQ:SNY) is looking to spin off its India consumer unit, according to the Economic Times. Reportedly, the ...See details»


Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study

Source from : on MSN - 10 days ago

Sanofi SNY and partner Regeneron REGN announced positive data from the pivotal phase III BOREAS study, which evaluated their blockbuster drug, Dupixent (dupilumab), for treating chronic obstructive ...See details»

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

Source from : Reuters - 10 days ago

Shares in Sanofi and Regeneron surged after they said in a joint statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function ...See details»


Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals

Source from : Seeking Alpha on MSN - 10 days ago

Dupixent met the main goal and all key secondary goal in a phase 3 trial to treat adults who were current or former ...See details»


Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

Source from : ENDPOINTS NEWS - 10 days ago

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning ...See details»

Sanofi cuts the price of its most prescribed insulin by 78 percent

Source from : Yahoo - 16 days ago

French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product ...See details»

Sanofi, joining other drug makers, slashes US insulin price

Source from : Medical Xpress - 16 days ago

French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers. Eli Lilly ...See details»

Sanofi to acquire Provention Bio in $2.9B deal

Source from : NJBIZ - 20 days ago

Following Sanofi‘s $35 million equity investment last month, the global health care company will acquire Red Bank-based Provention Bio Inc. for $25 per share, representing an equity value of ...See details»

Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium

Source from : Seeking Alpha - 7 days ago

Sanofi proposed to acquire Provention Bio for $2.9 billion in cash at a 273% premium over the previous closing price (before the deal announcement). The acquisition is expected to be a net ...See details»

Sanofi to cut US price of its most-prescribed insulin by 78%

Source from : Yahoo News - 14 days ago

(Reuters) -Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly ...See details»

Drug giant Sanofi becomes latest to cap US insulin prices

Source from : Yahoo News - 16 days ago

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of three major manufacturers of the drug to curb soaring costs of the lifesaving medication in the US. The French ...See details»

Sanofi: Sanofi and Regeneron Report Positive COPD Data, Raising Dupixent's Peak Sales Potential

Source from : Yahoo Finance - 10 days ago

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the ...See details»

Sanofi is the latest insulin maker to announce price cap

Source from : WTKR - 16 days ago

The announcement this week by Sanofi means the three largest insulin producers in the world have instituted price caps in recent weeks. Sanofi said Lantus 100 Units/mL will have a $35 per month ...See details»


Sanofi launches its first smart data sensor that records insulin injections in real time

Source from : BioWorld - 10 days ago

Sanofi SA is launching its first connected data collector for recording insulin injection in real time. The launch was reported at the Francophone Diabetes Society (SFD) congress in Montpellier, ...See details»